Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PMS2
REST API REST API
Homo sapiens
PMS2 is differentially expressed in 127 experiments: 48 organism parts: bone marrow, cerebral cortex, ... (46 more);, 47 disease states: normal, colorectal carcinoma, ... (45 more);, 29 cell types 156 cell lines 15 compound treatments and 39 other conditions.
Synonyms HNPCC4, PMSL2, H_DJ0042M02.9
Orthologs PMS2 (Bos taurus)   PMS1 (Saccharomyces cerevisiae)   ENSCING00000002674 (Ciona intestinalis)   PMS2 (Gallus gallus)   pms2 (Danio rerio)   Pms2 (Rattus norvegicus)   Pms2 (Mus musculus)   Pms2 (Drosophila melanogaster)   pms2 (Xenopus laevis)   PMS2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term reciprocal meiotic recombination, DNA binding, protein binding, DNA repair, ATPase activity, single-stranded DNA binding, mismatched DNA binding, ATP binding, nucleus, mismatch repair, response to drug, hydrolase activity, endonuclease activity, response to DNA damage stimulus, somatic recombination of immunoglobulin gene segments, ATP catabolic process, single base insertion or deletion binding, MutLalpha complex, MutSalpha complex binding, somatic hypermutation of immunoglobulin genes
InterPro Term DNA_mismatch_repair_N, DNA_mismatch_repair_C, MutL_C, ATPase-like_ATP-bd
UniProt Accession A5YRY4, P54278, C9J167, Q68D20
Gene-Disease Assocation MISMATCH REPAIR CANCER SYNDROME, POSTMEIOTIC SEGREGATION INCREASED, S. CEREVISIAE, 2; PMS2
Search EB-eye ENSG00000122512
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-MEXP-1251, E-GEOD-6919, E-GEOD-1402, ... (13 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-22560, E-GEOD-19639, E-GEOD-24147, E-GEOD-19480, E-MEXP-903, ... (15 experiments)

Factor Value U/D Experiments
CA46
1
E-MTAB-37
SNU5
1
E-MTAB-37
1A2
1
E-MTAB-37
HL-60
1
E-GEOD-24147
MHHPREB1
1
E-MTAB-37
DMS114
1
E-MTAB-37
150 more value(s).


Cell type

studied in E-GEOD-15893, E-GEOD-18811, E-GEOD-20033, E-TABM-130, E-GEOD-26672, ... (17 experiments)

Factor Value U/D Experiments
not specified
1
E-GEOD-11755
endothelial cell
1
E-GEOD-3998
peripheral blood mononuclear cell
1
E-GEOD-3026
vascular smooth muscle cell
1
E-TABM-130
mesenchymal stem cell
1
E-GEOD-9894
CXCR4 positive
1
E-GEOD-15893
23 more value(s).


Disease state

studied in E-MEXP-1922, E-GEOD-19743, E-GEOD-6872, E-MEXP-25, E-GEOD-23878, ... (22 experiments)

Factor Value U/D Experiments
control
1
E-GEOD-8121
CLL (Chronic Lymphocytic Leukemia)
1
E-GEOD-16455
squamous cell carcinoma
1
E-MTAB-37
benign prostatic hyperplasia
1
E-MEXP-2034
MDS-associated acute myeloid leukemia
1
E-MEXP-25
mesothelioma
1
E-MTAB-37
41 more value(s).


Compound treatment

studied in E-MEXP-1601, E-GEOD-1923, E-GEOD-15205, E-GEOD-412, E-GEOD-697, ... (12 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-697, E-TABM-868, E-MEXP-1958, E-GEOD-1923, E-MEXP-1601, ... (6 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
TNF
1
E-GEOD-15205
baseline propofol
1
E-GEOD-4386
Cxcl12
1
E-GEOD-7307
no estradiol
1
E-GEOD-20081
9 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-20499, E-GEOD-21589, ... (7 experiments)

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-TABM-147, E-GEOD-3013

Environmental stress
studied in E-GEOD-3720

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-361, E-MEXP-2340

Genotype
studied in E-MEXP-421, E-TABM-868

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (6 experiments)

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-666, E-MEXP-1648, ... (17 experiments)

individual id
studied in E-GEOD-19519

Injury
studied in E-GEOD-19743

Material type
studied in E-GEOD-9171

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-4525, E-GEOD-21750

Population
studied in E-MTAB-197

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-7307

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-19815

Tumor grading
studied in E-GEOD-4290

Processing time: 0.533 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM